LU86290A1 - Compositions pharmaceutiques a base de 3-aminopropoxyindoles - Google Patents

Compositions pharmaceutiques a base de 3-aminopropoxyindoles Download PDF

Info

Publication number: LU86290A1
Authority: LU; Luxembourg
Prior art keywords: composition according; approximately; formula; component; treatment
Prior art date: 1985-02-05

Application number

LU86290A

Other languages

English (en)

French (fr)

Original Assignee

Sandoz Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-02-05

Filing date

1986-02-04

Publication date

1986-09-02

1985-02-05 Priority claimed from GB858502887A external-priority patent/GB8502887D0/en

1986-02-04 Application filed by Sandoz Sa filed Critical Sandoz Sa

1986-09-02 Publication of LU86290A1 publication Critical patent/LU86290A1/fr

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 8
239000000203 mixture Substances 0.000 claims description 30
238000011282 treatment Methods 0.000 claims description 24
150000001875 compounds Chemical class 0.000 claims description 22
UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 claims description 19
229960001035 bopindolol Drugs 0.000 claims description 19
150000003839 salts Chemical class 0.000 claims description 13
JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 claims description 12
229960001523 chlortalidone Drugs 0.000 claims description 12
239000002934 diuretic Substances 0.000 claims description 12
230000001882 diuretic effect Effects 0.000 claims description 9
NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims description 9
229960004569 indapamide Drugs 0.000 claims description 9
239000002253 acid Substances 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 7
208000024172 Cardiovascular disease Diseases 0.000 claims description 6
102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 6
108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 6
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
239000008024 pharmaceutical diluent Substances 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
208000035475 disorder Diseases 0.000 claims description 3
239000003087 receptor blocking agent Substances 0.000 claims description 2
239000002981 blocking agent Substances 0.000 claims 1
238000000034 method Methods 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
206010020772 Hypertension Diseases 0.000 description 15
230000000694 effects Effects 0.000 description 11
230000036772 blood pressure Effects 0.000 description 10
230000003442 weekly effect Effects 0.000 description 9
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 8
239000004480 active ingredient Substances 0.000 description 7
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
239000008101 lactose Substances 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
229920002261 Corn starch Polymers 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
230000000903 blocking effect Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000008120 corn starch Substances 0.000 description 5
239000008107 starch Substances 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
241001440269 Cutina Species 0.000 description 4
239000004359 castor oil Substances 0.000 description 4
235000019438 castor oil Nutrition 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000002526 effect on cardiovascular system Effects 0.000 description 4
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 4
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
239000002876 beta blocker Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
229940030606 diuretics Drugs 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
206010002383 Angina Pectoris Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000004880 Polyuria Diseases 0.000 description 2
229920003110 Primojel Polymers 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
239000013543 active substance Substances 0.000 description 2
206010003119 arrhythmia Diseases 0.000 description 2
230000006793 arrhythmia Effects 0.000 description 2
229940030611 beta-adrenergic blocking agent Drugs 0.000 description 2
239000000470 constituent Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000035619 diuresis Effects 0.000 description 2
238000013265 extended release Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-M malonate(1-) Chemical compound OC(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-M 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
229960003712 propranolol Drugs 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
VONDEAICGOZHRO-UHFFFAOYSA-N 3-(1h-indol-2-yloxy)propan-1-amine Chemical class C1=CC=C2NC(OCCCN)=CC2=C1 VONDEAICGOZHRO-UHFFFAOYSA-N 0.000 description 1
BGQHPLYSXBZMQG-UHFFFAOYSA-N 4-(2-Hydroxy-3-tert-butylaminopropoxy)-2-methylindole Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(O)CNC(C)(C)C BGQHPLYSXBZMQG-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000464 adrenergic agent Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
229960002576 amiloride Drugs 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
239000008298 dragée Substances 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000007661 gastrointestinal function Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
229960004255 nadolol Drugs 0.000 description 1
VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
229960002508 pindolol Drugs 0.000 description 1
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000029865 regulation of blood pressure Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
229960004605 timolol Drugs 0.000 description 1
230000003867 tiredness Effects 0.000 description 1
208000016255 tiredness Diseases 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
229940100640 transdermal system Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LU86290A 1985-02-05 1986-02-04 Compositions pharmaceutiques a base de 3-aminopropoxyindoles LU86290A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB8502887		1985-02-05
GB858502887A GB8502887D0 (en)	1985-02-05	1985-02-05	Pharmaceutical compositions
DE3505740		1985-02-20
DE3505740		1985-02-20

Publications (1)

Publication Number	Publication Date
LU86290A1 true LU86290A1 (fr)	1986-09-02

Family

ID=25829545

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU86290A LU86290A1 (fr)	1985-02-05	1986-02-04	Compositions pharmaceutiques a base de 3-aminopropoxyindoles

Country Status (15)

Country	Link
AT (1)	AT393960B (de)
AU (1)	AU5293286A (de)
BE (1)	BE904146A (de)
CH (1)	CH667388A5 (de)
DK (1)	DK52186A (de)
ES (1)	ES8800597A1 (de)
FR (1)	FR2576788A1 (de)
GB (1)	GB2173399A (de)
GR (1)	GR860307B (de)
HU (1)	HU196125B (de)
IT (1)	IT1203737B (de)
LU (1)	LU86290A1 (de)
NL (1)	NL8600137A (de)
PH (1)	PH23077A (de)
PT (1)	PT81953B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2677886B1 (fr) *	1991-06-18	1995-03-31	Adir	Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale.
PL193976B1 (pl)	2002-07-01	2007-04-30	Pliva Krakow	Tabletka o przedłużonym działaniu zawierająca indapamid i sposób wytwarzania tabletki o przedłużonym działaniu zawierającej indapamid
DE102004062257A1 (de) *	2004-12-23	2006-07-06	Merckle Gmbh	Direkt verpresste Indapamid-Tabletten mit verzögerter Wirkstofffreisetzung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2738568A (en) *	1953-08-11	1956-03-20	Civitelli Gennaro	Rasp or file
AT273761B (de) *	1965-11-13	1969-08-25	Philipp August Sonn	Abziehvorrichtung für Ski-Stahlkanten
GB1260907A (en) *	1968-06-07	1972-01-19	Sandoz Ltd	Indole derivatives
US4139633A (en) *	1971-06-15	1979-02-13	Ciba-Geigy Corporation	Pharmaceutical preparations for the treatment of hypertonia
AT336176B (de) *	1971-12-10	1977-04-25	Sandoz Ag	Verfahren zur herstellung eines pharmazeutischen praparates
GB1425033A (en) *	1972-03-10	1976-02-18	Hendrickson A E	Data signal recogniion apparatus
US3956616A (en) *	1974-05-06	1976-05-11	Knollenberg Robert G	Method and apparatus for generating a statistical basis
DE2635209C2 (de) *	1975-08-15	1983-01-27	Sandoz-Patent-GmbH, 7850 Lörrach	4-(2-Benzoyloxy-3-tert.butylamino-propoxy)-2-methylindol, dessen (S)-Enantiomeres, deren Säureadditionssalze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Heilmittel
AT341396B (de) *	1976-03-01	1978-02-10	C O Oberg & Co Ab	Schleifvorrichtung
DE2638716A1 (de) *	1976-08-27	1978-03-02	Ici Gmbh	Antihypertensiva
DE3140432C2 (de) *	1980-10-13	1985-10-10	Hitachi, Ltd., Tokio/Tokyo	Drehzahlregelschaltung
US4388320A (en) *	1981-03-09	1983-06-14	Sandoz Ltd.	3-Aminopropoxyaryl derivative in the treatment of tremor
DD205834B1 (de) *	1982-03-30	1985-12-18	Mansfeld Kombinat W Pieck Veb	Schnellwechseleinrichtung fuer werkzeuge
FR2529785A1 (fr) *	1982-07-09	1984-01-13	Adir	Composition pharmaceutique a base d'indapamide et de 8-(3-tertbutylamino 2-hydroxypropoxy)-thiachromanne

1986
- 1986-01-22 NL NL8600137A patent/NL8600137A/nl not_active Application Discontinuation
- 1986-01-22 HU HU86310A patent/HU196125B/hu unknown
- 1986-01-24 CH CH277/86A patent/CH667388A5/de not_active IP Right Cessation
- 1986-01-30 FR FR8601417A patent/FR2576788A1/fr active Pending
- 1986-01-31 BE BE1/011430A patent/BE904146A/fr not_active IP Right Cessation
- 1986-02-03 GR GR860307A patent/GR860307B/el unknown
- 1986-02-03 PT PT81953A patent/PT81953B/pt unknown
- 1986-02-03 AU AU52932/86A patent/AU5293286A/en not_active Abandoned
- 1986-02-03 GB GB08602601A patent/GB2173399A/en not_active Withdrawn
- 1986-02-03 DK DK52186A patent/DK52186A/da not_active Application Discontinuation
- 1986-02-04 PH PH33378A patent/PH23077A/en unknown
- 1986-02-04 LU LU86290A patent/LU86290A1/fr unknown
- 1986-02-04 AT AT0026186A patent/AT393960B/de not_active IP Right Cessation
- 1986-02-04 ES ES551634A patent/ES8800597A1/es not_active Expired
- 1986-02-04 IT IT47615/86A patent/IT1203737B/it active

Also Published As

Publication number	Publication date
FR2576788A1 (fr)	1986-08-08
ES8800597A1 (es)	1987-11-16
IT1203737B (it)	1989-02-23
DK52186D0 (da)	1986-02-03
GB2173399A (en)	1986-10-15
HU196125B (en)	1988-10-28
CH667388A5 (de)	1988-10-14
GB8602601D0 (en)	1986-03-12
ATA26186A (de)	1991-07-15
AT393960B (de)	1992-01-10
BE904146A (fr)	1986-07-31
AU5293286A (en)	1986-08-14
DK52186A (da)	1986-08-06
IT8647615A0 (it)	1986-02-04
GR860307B (en)	1986-05-27
PH23077A (en)	1989-04-10
PT81953A (en)	1986-03-01
PT81953B (en)	1987-12-21
ES551634A0 (es)	1987-11-16
NL8600137A (nl)	1986-09-01
HUT44934A (en)	1988-05-30

Publication	Publication Date	Title
EP0278821B1 (de)	1994-10-05	Verwendung von Morphinantagonisten zur Herstellung von Medikamenten mit immunmodulatorischer und antiviraler Wirkung, insbesondere bestimmt zur Behandlung von erworbenen Immunmangelzuständen
JP2002537326A5 (de)	2007-04-12
FR2792529A1 (fr)	2000-10-27	Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
BE1007024A5 (fr)	1995-02-21	Compositions a activite agoniste des recepteurs analogues a 5ht1, selective.
Billups et al.	1998	Mibefradil: a new class of calcium-channel antagonists
LU86290A1 (fr)	1986-09-02	Compositions pharmaceutiques a base de 3-aminopropoxyindoles
CA2654210C (fr)	2013-06-25	Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant
EP0966276B1 (de)	2003-12-10	Verwendung von beta-3-adrenorezeptoragonisten zur herstellung von wundheilmitteln
EP2280700A2 (de)	2011-02-09	Kombination aus dronedaron und mindestens einem diuretikum sowie therapeutische anwendung davon
FR2587213A1 (fr)	1987-03-20	Medicament pour le traitement de la dependance aux psychostimulants
EP1265614B1 (de)	2005-06-01	Molsidominhaltige oral anzuwendende verabreichungsform mit verzögerter wirkstoffabgabe
FR2579893A1 (de)	1986-10-10
WO1990009171A1 (fr)	1990-08-23	Preparations medicamenteuses cardio-protectrices comprenant l'amiodarone, un derive nitre, notamment le dinitrate d'isosorbide et facultativement un beta-bloqueur
WO2004037256A1 (fr)	2004-05-06	Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
EP1115399B1 (de)	2005-03-02	Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten
WO2003057198A1 (fr)	2003-07-17	Compositions pharmaceutiques a liberation modifiee
OA10583A (en)	2002-07-10	Microgranules de dérivés de 5-nitro imidazole
Nies et al.	1967	Recent concepts in the clinical pharmacology of anithypertensive drugs
EP0412877A1 (de)	1991-02-13	Orale Arzneiform zur Verbesserung der Bioverfügbarkeit
WO2025219389A1 (fr)	2025-10-23	Compositions contenant une combinaison synergique de mémantine et de vitamine d
FR2916142A1 (fr)	2008-11-21	Forme pharmaceutique comprenant du (10-[(3s)-1-azabicyclo [2.2.2]oct-3-ylmethyl]-10h-phenothiazine se presentant sous une forme appropriee pour l'administration d'unde dose journaliere comprise entre 1 et 3 mg
EP1303277A1 (de)	2003-04-23	Pharmazuetische zusammenstellung auf basis von cocaethylen und dessen verwendung zur behandlung der abhängigkeit von psychoaktiven substanzen
LU85951A1 (fr)	1986-01-22	Composition pharmaceutique utilisable dans le traitement des maladies des voies urinaires,son procede de preparation et methode d'utilisation de cette composition
BE894110A (fr)	1982-12-01	Utilisation de la trazodone dans le traitement des ulceres gastro-intestinaux
WO2007144501A2 (fr)	2007-12-21	Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire